Alkaline phosphatase level increase with initiation of hormone therapy for prostate cancer portends poor prognosis with rapid progression to bone metastases: a case report and review of the literature.
A 73-year-old man with localized prostate cancer was treated with androgen deprivation and radiation therapy. Staging evaluation showed no evidence of metastatic disease. After initiation of androgen deprivation therapy, the patient developed a marked increase in serum alkaline phosphatase (ALP). Despite continuation of hormonal ablation and completion of radiation therapy, ALP and prostate-specific antigen levels continued to increase. Bone metastases were documented 6 months after diagnosis. In this report, we explore the role of serum ALP as an indicator for patients who develop early metastases and thus might benefit from early initiation of aggressive secondary treatments such as chemotherapy.
Brown
Michael W
MW
National Institutes of Health/National Cancer Institute, Bethesda, MD 20892, USA.
Singh
Anurag K
AK
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000201:enzymology* / Q000556:secondary* / Q000628:therapy; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy*
D000726:Androgen Antagonists; D000469:Alkaline Phosphatase